Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPTIC: Optimising and Personalising Immunological Therapy in Relapsed CLL
2024-513917-11-01Phase 2Authorised
- Sponsor
- Medical University of Lublin
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of venetoclax, obinutuzumab and daratumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Medical University of Lublin. Primary endpoints: Safety and MTD/MAD of daratumumab in VOD regimen and uMRD rate in VO regimen by risk group. Planned start May 2026; status: authorised.
02
Drugs
venetoclaxobinutuzumabdaratumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-513917-11-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513917-11-01.